about
Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis.Expression of recombinant human coagulation factor VII by the Lizard Leishmania expression system.Factor VII and protein C are phosphatidic acid-binding proteins.N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbitsThe acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Recombinant activated factor VII in clinical practice: a 2014 update.Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects.The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.Recombinant activated coagulation factor VII and prothrombin complex concentrates are equally effective in reducing hematoma volume in experimental warfarin-associated intracerebral hemorrhage.Management of bleeding in patients taking FXa and FIIa inhibitors.A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors.Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias.Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment.Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
P2860
Q31102998-9763BD74-FE30-45D2-8BE5-C20EFF1F4D1BQ33756657-619401DE-6C5B-421C-BA9F-810D8ED42EF5Q33983293-49F964B4-B11E-4888-B770-9CA460001267Q35202023-94599B0C-DB5B-428F-9399-19CA384AD215Q37200399-ACF3F7D2-4B92-4ED8-977E-9673AD9F61E1Q37277251-F3D01619-9567-43E3-AAB3-C9629F039973Q37552621-C28607B4-0A5C-4959-BA3F-9B24E6060C82Q38060224-DC2BC9F0-E426-4865-A21E-853193BD1D87Q38228494-8C4CA3FA-66E4-4645-9005-07381B6C7492Q38739036-2E93B731-3215-4B66-9228-17A93CD4B61BQ38817825-636CF349-700F-4681-BBE5-5C7F6DB4076EQ39420691-E86F6F04-CED8-475D-88E9-43795E789357Q39591239-573F82BC-B48D-4E5B-B4AE-8DCAE0CF47A9Q42024671-25227617-E2BC-49C8-8B4B-6062908AB230Q42360054-D3988F67-2D39-4BB1-811F-ABB0B4BBB977Q43075526-180A2B82-E135-48EF-BBC8-2D869FDF82F7Q45007433-D17C603E-1C90-4BD5-AED2-226F0C9F1D6EQ45874627-6ABBB580-E0FC-453B-8AD0-BD7CF9BA1E78Q45881838-73E5089B-6ED3-43CB-86A5-462F0F8E0199Q47324534-EB8CC713-6C30-4C43-953B-22EF38035D93Q48207455-05C65F49-77CE-4A48-BE3D-F2880E02098AQ55346403-09D94BB1-92B0-472B-A043-E25311F7CEF7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
First 20 years with recombinant FVIIa (NovoSeven).
@en
First 20 years with recombinant FVIIa
@nl
type
label
First 20 years with recombinant FVIIa (NovoSeven).
@en
First 20 years with recombinant FVIIa
@nl
prefLabel
First 20 years with recombinant FVIIa (NovoSeven).
@en
First 20 years with recombinant FVIIa
@nl
P2860
P1433
P1476
First 20 years with recombinant FVIIa (NovoSeven).
@en
P2093
P2860
P304
P356
10.1111/J.1365-2516.2010.02352.X
P577
2011-01-01T00:00:00Z